| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Presentations collectively highlight pilavapadin's potential to improve pain management care for patients with diabetic peripheral neuropathic pain (DPNP)
Breadth of the data across Phase 2 program to be discussed at Arrowhead's 19th Annual Pain Summit
THE WOODLANDS, Texas, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced the presentation of clinical data for its investigational, AAK1-inhibitor, pilavapadin, for the treatment of diabetic peripheral neuropathic pain (DPNP) at three upcoming medical meetings.
Details for the presentations are as follows:
NeuroDiab, September 11-14 in Bucharest, Romania:
- Lecture 3: New Promise for Painful Diabetic Neuropathy: Results from recently finished clinical trials of Pilavapadin, an oral, non-opioid, AAK1 inhibitor for diabetic peripheral neuropathic pain
- Date: Saturday, September 13, 2025
- Time: 11:15 a.m. CEST
- Presenter: Rodica Pop-Busui M.D., Ph.D., Jordan Schnitzer Chair in Diabetes, Professor of Medicine and Division Head, Endocrinology, Diabetes and Clinical Nutrition Director, Harold Schnitzer Diabetes Center, Oregon Health & Science University
European Association for the Study of Diabetes (EASD), September 16-19 in Vienna, Austria:
- Oral Presentation: Pilavapadin, an oral, non-opioid, AAK1 inhibitor for diabetic peripheral neuropathic pain (DPNP): results from a Phase 2b, dose-ranging, randomized, placebo-controlled, multicenter study
- Date: Wednesday, September 17, 2025
- Time: 10:30 a.m. CEST
- Location: Sofia Hall
- Presenter: Rodica Pop-Busui M.D., Ph.D., Jordan Schnitzer Chair in Diabetes, Professor of Medicine and Division Head, Endocrinology, Diabetes and Clinical Nutrition Director, Harold Schnitzer Diabetes Center, Oregon Health & Science University
Arrowhead's 19th Annual Pain Therapeutics Summit, October 13-14 in San Diego, CA:
- Poster: Pilavapadin in Neuropathic Pain: Results from the Phase 2b PROGRESS Trial in Patients with Diabetic Peripheral Neuropathic Pain
- Date: Monday, October 13, 2025
- Time: 3:25 p.m. PT
- Presenter: Suma Gopinathan Ph.D., VP Clinical Development, Lexicon Pharmaceuticals
Posted In: LXRX
